Lonvoguran ziclumeran (lonvo-z)

Name: Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: C1 esterase inhibitors
Published: 2026-09-14T15:39:06-04:00

Hereditary angioedema

Also known as NTLA-2002

Manufacturer: Intellia Therapeutics
Regulatory submission: Rolling BLA initiated April 2026 and accepted September 2026
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

C1 esterase inhibitors

1 evidence topic · 1 source

International/Canadian guideline: first-line long-term prophylaxis options

“Berotralstat, donidalorsen, garadacimab, lanadelumab, or pdC1INH could be used as first-line therapy for long-term prophylaxis in patients with HAE due to C1INH deficiency.” (opens the source at this quote in a new tab)